Group One Trading
CTKB icon

Group One Trading’s Cytek Biosciences CTKB Stock Holding History

Group One Trading’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-700
Closed -$3.86K – 7511
2023
Q3 		$3.86K Buy
700
+500
+250% +$4.01K ﹤0.01% 6818
2023
Q2 		$1.71K Buy
+200
New +$1.79K ﹤0.01% 7127

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Group One Trading's CTKB Position: Q1 2026 in Review

Group One Trading increased its Cytek Biosciences (CTKB) stake by 47% in Q1 2026, buying an estimated $3.31K and bringing the position to 2,200 shares worth $9.61K. The position accounts for ﹤0.01% of the portfolio, ranked #6396.

Group One Trading first reported a position in CTKB in Q4 2022 and has held it in 5 quarters since. The position peaked at $68.3K in Q4 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Group One Trading held 2,200 shares of Cytek Biosciences worth $9.61K as of Q1 2026.
  • Group One Trading bought 700 Cytek Biosciences shares in Q1 2026, an estimated $3.31K.
  • Cytek Biosciences made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6396 holding.
  • Group One Trading first reported a position in Cytek Biosciences in Q4 2022 and has held it in 5 quarters since.
  • Group One Trading's Cytek Biosciences position peaked at $68.3K in Q4 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.